PIRAMAL PHARMA Financial Statement Analysis
|
||
|
The Revenues of PIRAMAL PHARMA have decreased by -3.08% YoY .
The Earnings Per Share (EPS) of PIRAMAL PHARMA has decreased by Negative YoY. |
||
PIRAMAL PHARMA Last 5 Annual Financial Results
[BOM: 543635|NSE : PPLPHARMA]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹8,869 Cr | ₹9,151 Cr | ₹8,171 Cr | ₹7,082 Cr | ₹6,559 Cr |
| Expenses | ₹7,977 Cr | ₹7,733 Cr | ₹7,001 Cr | ₹6,453 Cr | ₹5,609 Cr |
| Operating Profit (Excl OI) | ₹892 Cr | ₹1,418 Cr | ₹1,171 Cr | ₹628 Cr | ₹950 Cr |
| Other Income | ₹242 Cr | ₹162 Cr | ₹201 Cr | ₹225 Cr | ₹276 Cr |
| Interest | ₹341 Cr | ₹422 Cr | ₹448 Cr | ₹344 Cr | ₹198 Cr |
| Depreciation | ₹831 Cr | ₹816 Cr | ₹741 Cr | ₹677 Cr | ₹586 Cr |
| Profit Before Tax | ₹-176 Cr | ₹415 Cr | ₹179 Cr | ₹-120 Cr | ₹485 Cr |
| Profit After Tax | ₹-326 Cr | ₹91 Cr | ₹18 Cr | ₹-186 Cr | ₹376 Cr |
| Consolidated Net Profit | ₹-326 Cr | ₹91 Cr | ₹18 Cr | ₹-186 Cr | ₹376 Cr |
| Earnings Per Share (Rs) | ₹-2.46 | ₹0.69 | ₹0.13 | ₹-1.56 | ₹3.17 |
| PAT Margin (%) | -3.10 | 0.86 | 0.19 | -2.30 | 5.15 |
| ROE(%) | -4.04 | 1.14 | 0.24 | -2.77 | 6.11 |
| ROCE(%) | 1.24 | 6.61 | 5.07 | 1.95 | 7.10 |
| Total Debt/Equity(x) | 0.68 | 0.59 | 0.58 | 0.81 | 0.60 |
Key Financials |
||
| Market Cap | : | ₹ 22,379.2 Cr |
| Revenue (TTM) | : | ₹ 8,869.1 Cr |
| Net Profit(TTM) | : | ₹ -383.1 Cr |
| EPS (TTM) | : | ₹ -2.9 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| PIRAMAL PHARMA | -0.1% | 1.6% | -14.4% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.9% | 5.6% | 14.1% |
| DIVIS LABORATORIES | 1.2% | 3.7% | -1.2% |
| TORRENT PHARMACEUTICALS | 4.4% | 10.3% | 42.1% |
| CIPLA | -1.7% | 3.1% | -4.2% |
| DR REDDYS LABORATORIES | 0.2% | 5.7% | 6% |
| MANKIND PHARMA | 0.1% | 5.5% | 10.6% |
| LUPIN | 2.5% | 9.1% | 27% |
| ZYDUS LIFESCIENCES | 4.5% | 5.7% | 15.1% |
PIRAMAL PHARMA Revenues
[BOM: 543635|NSE : PPLPHARMA]
| Y-o-Y | -3.08 % |
| 5 Yr CAGR | 7.83 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹8,869 Cr | -3.08 | |
| Mar2025 | ₹9,151 Cr | 11.99 | |
| Mar2024 | ₹8,171 Cr | 15.39 | |
| Mar2023 | ₹7,082 Cr | 7.97 | |
| Mar2022 | ₹6,559 Cr | - | |
PIRAMAL PHARMA Operating Profit
[BOM: 543635|NSE : PPLPHARMA]
| Y-o-Y | -37.05 % |
| 5 Yr CAGR | -1.54 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹892 Cr | -37.05 | |
| Mar2025 | ₹1,418 Cr | 21.13 | |
| Mar2024 | ₹1,171 Cr | 86.32 | |
| Mar2023 | ₹628 Cr | -33.85 | |
| Mar2022 | ₹950 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -35.05 % |
| 5 Yr CAGR | -8.70 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 10.06% | -35.05 | |
| Mar2025 | 15.49% | 8.17 | |
| Mar2024 | 14.32% | 61.44 | |
| Mar2023 | 8.87% | -38.74 | |
| Mar2022 | 14.48% | - | |
PIRAMAL PHARMA Profit After Tax
[BOM: 543635|NSE : PPLPHARMA]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹-326 Cr | Negative | |
| Mar2025 | ₹91 Cr | 411.39 | |
| Mar2024 | ₹18 Cr | Positive | |
| Mar2023 | ₹-186 Cr | Negative | |
| Mar2022 | ₹376 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | -3.1 % | Negative | |
| Mar2025 | 0.86 % | 352.63 | |
| Mar2024 | 0.19 % | Positive | |
| Mar2023 | -2.3 % | Negative | |
| Mar2022 | 5.15 % | - | |
PIRAMAL PHARMA Earnings Per Share (EPS)
[BOM: 543635|NSE : PPLPHARMA]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹-2.46 | Negative | |
| Mar2025 | ₹0.69 | 430.77 | |
| Mar2024 | ₹0.13 | Positive | |
| Mar2023 | ₹-1.56 | Negative | |
| Mar2022 | ₹3.17 | - | |
PIRAMAL PHARMA Return on Capital Employed (ROCE)
[BOM: 543635|NSE : PPLPHARMA]
| Y-o-Y | -81.24 % |
| 5 Yr CAGR | -35.35 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 1.24% | -81.24 | |
| Mar2025 | 6.61% | 30.37 | |
| Mar2024 | 5.07% | 160.00 | |
| Mar2023 | 1.95% | -72.54 | |
| Mar2022 | 7.1% | - | |
PIRAMAL PHARMA Share Price vs Sensex
| Current Share Price | : | ₹168.1 |
| Current MarketCap | : | ₹ 22,379.2 Cr |
| Updated EOD on | : | Jul 08,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| PIRAMAL PHARMA | -0.1% |
1.6% |
-14.4% |
| SENSEX | -0.5% |
3% |
-8.5% |
PIRAMAL PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE HEALTHCARE | 0.2% | 4.9% | 11.2% |
| BSE 500 | -0.8% | 1.9% | -3.3% |
| BSE SELECT IPO INDEX | -0.9% | 5.2% | -8.1% |
| BSE 1000 | -0.9% | 2.1% | -2.9% |
| BSE 400 MIDSMALLCAP INDEX | -1.2% | 1.8% | 0.1% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY PHARMA | 1% | 4.9% | 15.4% |
| NIFTY HEALTHCARE INDEX | 0.5% | 4.8% | 11.6% |
| NIFTY500 HEALTHCARE INDEX | 0.2% | 4.7% | NA |
| NIFTY MIDSMALL HEALTHCARE | 0% | 3.9% | 14.7% |
| NIFTY SMALLCAP 50 | -0.5% | 4.5% | 1.3% |
You may also like the below Video Courses
FAQ about PIRAMAL PHARMA Financials
How the annual revenues of PIRAMAL PHARMA have changed ?
The Revenues of PIRAMAL PHARMA have decreased by -3.08% YoY .
How the Earnings per Share (EPS) of PIRAMAL PHARMA have changed?
The Earnings Per Share (EPS) of PIRAMAL PHARMA has decreased by Negative YoY .
Check out Intrinsic Value of Peers of PIRAMAL PHARMA
Compare Stock Analytics of Peers of PIRAMAL PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
